Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Zhongyu Yuan"'
Autor:
Cong Xue, Xin Hua, Fei Xu, Ying Lin, Ruoxi Hong, Lehong Zhang, Yanxia Shi, Yuan-Qi Zhang, Kuikui Jiang, Yong-Yi Zhong, Zhongyu Yuan, Shusen Wang, Jia Jia Huang, Zhiyong Wu, Wen Xia, Jian-Li Zhao, Xiwen Bi, Xin An
Publikováno v:
Journal of Clinical Oncology. 39:1003-1003
1003 Background: For metastatic breast cancer with hormone receptor-positive and HER2-positive, no evidence showed that which first-line regimens were preferred, either anti-HER2 therapy plus endocrine therapy or anti-HER2 therapy plus chemotherapy.
Autor:
Heng Huang, Xin An, Kuikui Jiang, Zhongyu Yuan, Fei Xu, Wen Xia, Shusen Wang, Yanxia Shi, Lehong Zhang, Xi Wang, Xin Hua, Cong Xue, Li Cai, Qian-Jun Chen, Jun Tang, Ruoxi Hong, Wang-Zhong Li, Xiwen Bi, Jia Jia Huang, Ying Lin
Publikováno v:
Journal of Clinical Oncology. 39:521-521
521 Background: Recent clinical trials and meta-analysis have suggested the benefit of adding capecitabine to standard chemotherapy in early-stage triple negative breast cancer (TNBC). We aimed to develop an individualized prediction model to quantif
Autor:
Jian Zeng, Yanxia Shi, Shusen Wang, Xin-Mei Liu, Jun Tang, Li Zhao, Lehong Zhang, Jia Jia Huang, Zhongyu Yuan, Xi Wang, Xianming Wang, Yong-Li Ke, Qian-Jun Chen, Danmei Pang, Heng Huang, Roujun Peng, Ying Lin, Fei Xu, Li Cai, Anqin Zhang
Publikováno v:
Journal of Clinical Oncology. 38:507-507
507 Background: Triple-negative breast cancer (TNBC) has a relatively high relapse rate and poor outcome after standard therapy among all subtypes of breast cancer. Effective strategies to reduce risk of relapse and death are unmet medical needs. Met
Autor:
Shusen Wang, Ruoxi Hong, Xiwen Bi, Anqin Zhang, Danmei Pang, Yi Jiang, Qiufan Zheng, Kuikui Jiang, Wen Xia, Zhongyu Yuan, Qing Zhang, Ruilian Xu, Fei Xu, Haibo Zhang, Zhiyong Wu, Yun Hong, Xianming Wang, Jia Jia Huang, Xin An, Qianyi Lu
Publikováno v:
Journal of Clinical Oncology. 38:e12511-e12511
e12511 Background: The role of secondary prophylaxis with pegfilgrastim (brand name: Jinyouli) in Chinese breast cancer patients has not been fully evaluated. We assessed the efficacy and safety of pegfilgrastim in secondary prophylaxis of chemothera
Autor:
Hao Hu, Shusen Wang, Qianyi Lu, Fei Xu, Kuikui Jiang, Yanxia Shi, Xiwen Bi, Cong Xue, Zhongyu Yuan, Jia Jia Huang, Kun Zhao, Wen Xia
Publikováno v:
Journal of Clinical Oncology. 37:e18349-e18349
e18349 Background: Guidelines recommend primary prophylaxis(PP) use for patients receiving chemotherapy regimens with a high risk of febrile neutropenia (FN), which is 20% or higher. This study aim to evaluate the cost effectiveness of PP with pegfil
Autor:
Yuee Teng, Zhongyu Yuan, Zefei Jiang, Huiping Li, Shude Cui, Yongsheng Wang, Binghe Xu, Xichun Hu, Xiaojia Wang, Pin Zhang, Hongming Pan, Qiang Yao, Junlan Yang, Zhongsheng Tong, Qingyuan Zhang, Tao Sun
Publikováno v:
Journal of Clinical Oncology. 36:1003-1003
1003Background: Utidelone, a genetically engineered epothilone analog, showed excellent efficacy in phase II and III trials in terms of PFS as a primary end point and ORR as a secondary end point. ...
Autor:
Yanxia Shi, Qiufan Zheng, Huimin Yuan, Roujun Peng, Quchang Ouyang, Danmei Pang, Fei Xu, Shusen Wang, Zhongyu Yuan, Wen Xia
Publikováno v:
Journal of Clinical Oncology. 35:1066-1066
1066 Background: Fulvestrant is potent for treatment of hormone receptor (HR)-positive advanced breast cancer (ABC); however, few data exist for this regimen as maintenance endocrine treatment after chemotherapy (CT). In our phase 2 trial, we aimed t
Autor:
Shude Cui, Pin Zhang, Tao Sun, Yuee Teng, Zefei Jiang, Qingyuan Zhang, Wang Xiao Jia, Xichun Hu, Binghe Xu, Zhongyu Yuan
Publikováno v:
Journal of Clinical Oncology. 34:1004-1004
1004Background: Utidelone, a genetically engineered epothilone analog, is a microtubule stabilizing agent that showed promising activities in phase I and phase II trials. In this report, a multi-ce...